Through the rights issue of units, Xspray is expected to receive approximately SEK 300 million, with two warrant series approximately amounting together up to an additional SEK 300 million upon full exercise.
Xspray Pharma AB (publ) is a pharmaceutical company that specializes in using its patented HyNap-technology to develop improved versions of existing protein kinase inhibitors (PKIs) for cancer treatment. The company's goal is to become a leader in the development of improved PKIs for cancer treatment. Xspray’s shares are listed on Nasdaq Stockholm.
Vinge’s team primarily consisted of Dain Hård Nevonen, Linnéa Sellström and Adrian Filipovic.
